Clinical trial
A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in…
NCT00241449 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00241449 |
|---|---|
| Title | A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer |
| Official title | A Double-blind, Randomized, Multicentre Trial Comparing the Efficacy and Tolerability of 250mg of Faslodex (Long Acting ICI 182,780) With 20mg of Nolvadex (Tamoxifen) in Postmenopausal Women With Advanced Breast Cancer |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer, Metastasis |
| Intervention type | Drug |
| Interventions | Fulvestrant, Tamoxifen |
| Enrollment | 51 |
| Start date | Nov 1, 1998 |
| Primary completion | Mar 1, 2007 |
| Completion | Jan 1, 2012 |
| First posted | Oct 19, 2005 |
| Last update posted | Jun 6, 2012 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, Finland, France, Germany, Hungary, Ireland, Israel and 14 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: